ScopusElsevier Scopus
Status
Active
Coverage
2006–present
Source type
Journal
Open access
No
CiteScore
9.9
SJR · SCImago
1.287
Q1 SJR quartile
H-index
99
Best quartile
Q1 · 83rd pctile
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Drug Discovery | 27 / 161 | 83rd | Q1 |
Compare journals
Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Expert Opinion on Drug Discovery
Expert Opinion on Drug Discovery is Scopus-indexed (Q1, CiteScore 9.9), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Taylor and Francis Ltd..
Checked against the index lists dated .
ISSN 1746-0441Verify ISSN ↗1746-045XVerify ISSN ↗
Publisher: Taylor and Francis Ltd.
Scopus · Q1WoS · SCIEONOS
9.9
CiteScore 2025
Q1
Best quartile
2
Indexed in
Cost to publish: No APC data — check the publisher
Web of ScienceClarivate (SCIE/SSCI/AHCI/ESCI)
DOAJDirectory of Open Access Journals (live)
Not in DOAJ
Open accessNot registered as fully open access
ONOS · SubscriptionOne Nation One Subscription — full-text access
This journal is part of the ONOS national subscription — readers at an ONOS-subscribed Indian institution get full-text access to its articles at no cost.
Access depends on your institution’s ONOS participation; the subscribed title list is subject to revision.
Learn about ONOS Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Quick answers
Is Expert Opinion on Drug Discovery indexed in Scopus?
Yes — actively indexed in Scopus, coverage 2006–present, best quartile Q1, CiteScore 9.9.
What quartile is Expert Opinion on Drug Discovery in Scopus?
Expert Opinion on Drug Discovery is Q1 in Drug Discovery (rank 27 of 161), by CiteScore 2025.
What is the impact factor of Expert Opinion on Drug Discovery?
Expert Opinion on Drug Discovery is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 9.9, which places it in quartile Q1 at the 83rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.287, quartile Q1, with an H-index of 99.
Who publishes Expert Opinion on Drug Discovery and what is its ISSN?
Expert Opinion on Drug Discovery is published by Taylor and Francis Ltd. Its print ISSN is 1746-0441 and its online ISSN is 1746-045X.
Is Expert Opinion on Drug Discovery covered under ONOS in India?
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Is Expert Opinion on Drug Discovery in Web of Science?
Yes — indexed in the Science Citation Index Expanded.
Is Expert Opinion on Drug Discovery open access?
No — it is not registered as an open-access journal in DOAJ or Scopus.
How well cited is Expert Opinion on Drug Discovery? — open metrics via OpenAlex
Expert Opinion on Drug Discovery has an h-index of 114 and a 2-year mean of 7.1 citations per paper (OpenAlex). Its Scopus CiteScore is 9.9, quartile Q1. On 2-year citations it ranks #16 of 159 Scopus journals in Drug Discovery.
114
h-index
7.1
2-yr mean citations
1,444
i10-index
2,247
works indexed
76,534
total citations
2-yr mean citations, among Scopus journals in the same subject
#16 of 159 Top 11% Drug Discovery
Expert Opinion on Drug Discovery published 110 papers in 2025; its busiest recent year was 2020 with 145. 2026* is the year so far.
Main topics
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
Who publishes in Expert Opinion on Drug Discovery? — latest 96 articles, 2025–2026
In its latest 96 research articles (2025–2026), authors are most often from United States (26%), United Kingdom (10.9%) and China (6.8%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Are there integrity warnings for Expert Opinion on Drug Discovery? — indicators, not proof of misconduct
Scopus status: Active. 1 retracted paper is recorded (0.4 per 1,000 papers). The Problematic Paper Screener flags 1 of its papers. These are indicators to check, not findings against the journal.
- Scopus statusActive
- Retracted papers 1 · 0.4 per 1,000 papers
- Problematic Paper Screener flags 1 · 0.4 per 1,000 papers — mostly tortured phrases
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Official sources & links
Community experience: reader comments on this journal
Related journals
8 journals Journal Indexed in
Expert Opinion on Drug Metabolism and Toxicology Scopus Q2 WoS SCIE Expert Opinion on Drug Safety Scopus Q1 WoS SCIE Expert Opinion on Emerging Drugs Scopus Q1 WoS SCIE Expert Opinion on Investigational Drugs Scopus Q1 WoS SCIE Expert Opinion on Orphan Drugs Not in these indexes Expert Opinion on Pharmacotherapy Scopus Q2 WoS SCIE Expert Opinion on Therapeutic Patents Scopus Q1 WoS SCIE Expert Opinion on Therapeutic Targets Scopus Q1 WoS SCIE
← Back to Journal Finder
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.